United States Focal Segmental Glomerulosclerosis Market Insight
Published: 17 July 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
The United States Focal Segmental Glomerulosclerosis (FSGS) Market is projected to grow at a CAGR of around 7.1% over the forecast period, driven by the increasing prevalence of rare kidney diseases and ongoing advancements in nephrology treatment approaches.
United States Focal Segmental Glomerulosclerosis Market Forecasts to 2035
- The United States Focal Segmental Glomerulosclerosis Market size was estimated at approximately USD 1.12 Billion in 2025.
- The market is expected to grow at a CAGR of around 7.1% from 2025 to 2035.
- The United States Focal Segmental Glomerulosclerosis Market is projected to reach approximately USD 2.23 Billion by 2035.
Notable Insights for the United States Focal Segmental Glomerulosclerosis Market
- Segmentation based on treatment type indicates that Corticosteroids, Immunosuppressants, and Targeted Therapies account for nearly 67% of market revenue in 2025, supported by their widespread use in disease management and relapse prevention.
- Segmentation based on disease type shows that Primary FSGS holds nearly 62% market share in 2025, driven by increasing diagnosis rates and greater utilization of advanced diagnostic techniques.
- Growing adoption of precision medicine, biologic therapies, genetic testing, and specialized nephrology care programs contributes to more than 47% of new treatment utilization in 2025.
Download the eBook (ToC)
- Rising chronic kidney disease prevalence, increasing healthcare expenditure, expanded access to rare disease treatments, and ongoing clinical research account for nearly 59% of the key market growth drivers.
Research Methodologies Used to Analyze United States Focal Segmental Glomerulosclerosis Market
The United States Focal Segmental Glomerulosclerosis Market is analyzed using primary and secondary research methodologies to ensure accurate market estimates and forecasts. Primary research includes interviews with nephrologists, kidney disease specialists, hospital pharmacists, specialty care providers, biotechnology companies, pharmaceutical manufacturers, healthcare administrators, patient advocacy groups, and industry experts. Secondary research covers company annual reports, FDA publications, nephrology journals, healthcare databases, government healthcare statistics, reimbursement guidelines, clinical trial registries, and market intelligence databases. Data triangulation, competitive benchmarking, pricing analysis, regulatory assessment, market share evaluation, and statistical forecasting models are applied to validate findings and provide reliable market forecasts through 2035.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United States Focal Segmental Glomerulosclerosis Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States Focal Segmental Glomerulosclerosis Market
- Travere Therapeutics, Inc.
- Novartis AG
- Roche Holding AG
- Pfizer Inc.
- Sanofi S.A.
- Bristol Myers Squibb
- AstraZeneca PLC
- Vertex Pharmaceuticals Incorporated
- Calliditas Therapeutics AB
- Chinook Therapeutics, Inc.
Recent Developments:
- In May 2025, Travere Therapeutics continued advancing its kidney disease treatment portfolio through expanded clinical development programs targeting proteinuric kidney disorders, including FSGS.
- In February 2025, Novartis announced progress in nephrology-focused research initiatives aimed at developing innovative therapies for rare glomerular diseases and chronic kidney conditions.
Market Segmentation:
United States Focal Segmental Glomerulosclerosis Market, By Treatment Type
- Corticosteroids
- Immunosuppressants
- Targeted Therapies
- Biologics
- Supportive Care Therapies
United States Focal Segmental Glomerulosclerosis Market, By Application
- Primary FSGS
- Secondary FSGS
- Genetic FSGS
United States Focal Segmental Glomerulosclerosis Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Pharmacies
- Online Pharmacies
Expert Views:
The United States Focal Segmental Glomerulosclerosis Market is expected to witness strong growth through 2035, supported by increasing awareness of rare kidney diseases, advancements in precision medicine, expanding clinical research activities, and growing adoption of targeted nephrology therapies. Continued innovation in biologics, genetic testing technologies, biomarker-based diagnostics, and personalized treatment approaches is expected to improve patient outcomes and strengthen market expansion. Furthermore, increasing investments in rare disease research, supportive reimbursement frameworks, specialized kidney care centers, and healthcare infrastructure modernization are anticipated to create long-term opportunities for pharmaceutical manufacturers, biotechnology companies, healthcare providers, and nephrology specialists across the United States.
Author: Govind and Krishna By Decisions Advisors and Consulting